Analysts are on the Bearish side about Seres Therapeutics, Inc. (NASDAQ:MCRB) this week.

May 13, 2018 - By Vivian Currie

Seres Therapeutics, Inc. (NASDAQ:MCRB) Logo

Seres Therapeutics, Inc. (NASDAQ:MCRB) Ratings Coverage

Among 2 analysts covering Seres Therapeutics (NASDAQ:MCRB), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Seres Therapeutics had 3 analyst reports since January 11, 2018 according to SRatingsIntel. The stock of Seres Therapeutics, Inc. (NASDAQ:MCRB) earned “Buy” rating by Oppenheimer on Tuesday, March 20. The rating was maintained by Oppenheimer with “Buy” on Thursday, January 11. Cantor Fitzgerald maintained the stock with “Buy” rating in Thursday, March 8 report. Below is a list of Seres Therapeutics, Inc. (NASDAQ:MCRB) latest ratings and price target changes.

20/03/2018 Broker: Oppenheimer Rating: Buy Maintain
08/03/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $16.0 Maintain
11/01/2018 Broker: Oppenheimer Rating: Buy New Target: $19.0 Maintain

The stock increased 1.34% or $0.11 during the last trading session, reaching $8.32. About 121,326 shares traded. Seres Therapeutics, Inc. (NASDAQ:MCRB) has declined 31.05% since May 13, 2017 and is downtrending. It has underperformed by 42.60% the S&P500.

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. The company has market cap of $338.23 million. The Company’s lead product candidate is SER-109, a bacterial spore ecology, which has completed Phase II clinical study to treat multiply recurrent Clostridium difficile infection . It currently has negative earnings. The firm also develops SER-287 that is in Phase Ib clinical study in patients with mild-to-moderate ulcerative colitis; and SER-262, a synthetic microbiome therapeutic candidate, which is in Phase Ib study in patients with primary CDI.

More important recent Seres Therapeutics, Inc. (NASDAQ:MCRB) news were published by: Seekingalpha.com which released: “Seres Therapeutics’ (MCRB) CEO Roger Pomerantz on Q1 2018 Results – Earnings Call Transcript” on May 13, 2018, also Businesswire.com published article titled: “Seres Therapeutics to Host First Quarter 2018 Financial Results and Operational Progress Conference Call and …”, Streetinsider.com published: “Seres Therapeutics (MCRB) Reports Q1 Revenues Above Consensus” on May 09, 2018. More interesting news about Seres Therapeutics, Inc. (NASDAQ:MCRB) was released by: Streetinsider.com and their article: “Seres Therapeutics (MCRB) Presents New Preclinical Data Supporting the Development of Microbiome Therapeutics …” with publication date: April 17, 2018.

Seres Therapeutics, Inc. (NASDAQ:MCRB) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


WP Twitter Auto Publish Powered By : XYZScripts.com